J Korean Med Sci.  2010 Feb;25(2):251-256. 10.3346/jkms.2010.25.2.251.

Outcomes of Palivizumab Prophylaxis for Respiratory Syncytial Virus Infection in Preterm Children with Bronchopulmonary Dysplasia at a Single Hospital in Korea from 2005 to 2009

• Chang SG
• Park MS
• Yu JE

• KMID: 1779256
• DOI: http://doi.org/10.3346/jkms.2010.25.2.251

Abstract

This study was performed to evaluate the utilization and outcomes of palivizumab in high risk children born prematurely with chronic lung disease (CLD). A retrospective review of 128 patients was conducted from September 2004 to March 2009 at the Ajou University Hospital. All patients were diagnosed with CLD, were born at < or =35 weeks of gestation, were <2 yr old at the onset of respiratory syncytial virus (RSV) season, and had received medical therapy within six months prior to the RSV season. Fifty-three patients did not receive palivizumab prophylaxis and 75 patients received at least one dose of palivizumab. There were no statistically significant differences between the patients with and without palivizumab prophylaxis with regard to demographic characteristics and risk factors for RSV infection. There were no systemic adverse responses. Compliance with the course of prophylaxis was 92.2%. Hospitalization associated with RSV occurred in 12 cases (22.6%) in the group without prophylaxis and in three cases (4.0%) with prophylaxis. Palivizumab prophylaxis significantly reduced the frequency of RSV-related hospitalization in preterm children with CLD. This is the first retrospective review of palivizumab prophylaxis in Korea. Palivizumab is effective and well tolerated in high risk prematurely born children.

Keyword

Chronic Lung Disease; Preterm Children; Palivizumab Prophylaxis, Respiratory Syncytial Viruses; Hospitalization

MeSH Terms

Antibodies, Monoclonal/*therapeutic use
Antibodies, Monoclonal, Humanized
Antiviral Agents/*therapeutic use
Bronchopulmonary Dysplasia/*complications/diagnosis
Demography
Hospitalization
Humans
Infant
Infant, Newborn
Premature Birth
Republic of Korea
Respiratory Syncytial Virus Infections/complications/*prevention & control
Retrospective Studies
Risk Factors
Treatment Outcome
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antiviral Agents

Reference

1. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001. 344:1917–1928.

2. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000. 137:865–870.

3. Holman RC, Shay DK, Curns AT, Lingappa JR, Anderson LJ. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J. 2003. 22:483–490.

4. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006. 118:1774–1793.

5. Loughlin GM, Moscona A. The cell biology of acute childhood respiratory disease: therapeutic implications. Pediatr Clin North Am. 2006. 53:929–959.

6. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003. 289:179–186.

7. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child. 2009. 94:99–103.

8. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003. 143:5 Suppl. S150–S156.

9. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998. 102:531–537.

10. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001. 163:1723–1729.

11. Denny FW, Clyde WA Jr. Acute lower respiratory tract infections in nonhospitalized children. J Pediatr. 1986. 108:635–646.

12. Simoes EA. Respiratory syncytial virus infection. Lancet. 1999. 354:847–852.

13. Kim YK, Nyambat B, Hong YS, Lee CG, Lee JW, Kilgore PE. Burden of viral respiratory disease hospitalizations among children in a community of Seoul, Republic of Korea, 1995-2005. Scand J Infect Dis. 2008. 40:946–953.

14. Ahn KM, Chung SH, Chung EH, Koh YJ, Nam SY, Kim JH, Son JA, Park JY, Lee NY, Lee SI. Clinical characteristics of acute viral lower respiratory tract infections in hospitalized children in Seoul, 1996-1998. J Korean Med Sci. 1999. 14:405–411.

15. Kim MR, Lee HR, Lee GM. Epidemiology of acute viral respiratory tract infections in Korean children. J Infect. 2000. 41:152–158.

16. Choi EH, Lee HJ, Kim SJ, Eun BW, Kim NH, Lee JA, Lee JH, Song EK, Kim SH, Park JY, Sung JY. The association of newly identified respiratory viruses with lower respiratory tract infections in Korean children, 2000-2005. Clin Infect Dis. 2006. 43:585–592.

17. Lee EA, Jeong JH, Yu ST, Lee CW, Yoon HS, Park DS, Oh YK. Incidence and risk factors of rehospitalization with respiratory syncytial virus infection in premature infants. Korean J Pediatr. 2004. 47:510–514.

18. Centers for Disease Control and Prevention (CDC). Brief report: respiratory syncytial virus activity-United States, 2005-2006. MMWR Morb Mortal Wkly Rep. 2006. 55:1277–1279.

19. Oh PI, Lanctĵt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J. 2002. 21:512–518.

20. Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J. 2000. 19:1068–1071.

21. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M. Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008. 28:511–517.

22. Palivizumab Outcomes Registry Study Group. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol. 2003. 35:484–489.

23. Saji BT. Indications, efficacy and Safety of Anti-RS Virus Monoclonal Antibody Palivizumab (Synagis) for Pediatric Patients With Congenital Heart Diseases. J Korean Pediatr Cardiol Soc. 2007. 11:149–150.

24. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003. 112:1442–1446.

25. American Academy of Pediatrics. Red-book: 2006 report of the committee on infectious disease. 2006. 27th ed. Elk Grove, IL: American Academy of Pediatrics.